Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SID1 transmembrane family member 2 (SIDT2) is a highly glycosylated lysosomal membrane protein implicated in the transport of RNA and DNA across the lysosomal membrane during nucleic acid autophagy, as well as in the hydrolysis of certain lipids[1][2][3]. SIDT2 has a structural core reminiscent of hydrolases in the CREST superfamily and forms a dimer with eleven transmembrane helices per protomer[1]. It acts as a putative nucleic acid transporter essential for lysosomal nucleic acid degradation, immune activation through antiviral cytokine production, and cellular metabolism of lipids and glucose[1][2][3]. SIDT2 is expressed in metabolically active tissues such as the liver, brain, and kidney, and its deficiency has been linked to metabolic, cardiovascular, inflammatory, and neurodegenerative disorders[1][3]. Although not a canonical drug target with approved therapeutics, it is of strong interest due to its fundamental roles in autophagy, immune response, and metabolism[1][2][3][6].
Not established for drugs; functionally implicated in nucleic acid and lipid transport/hydrolysis, immune activation, and metabolic regulation[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SID1 transmembrane family member 2 (SIDT2).